Effects of Specific Bioactive Collagen Peptides in Combination with Concurrent Training on Running Performance and Indicators of Endurance Capacity in Men: A Randomized Controlled Trial.
Simon Jerger, Patrick Jendricke, Christoph Centner, Kevin Bischof, Jan Kohl, Simon Keller, Albert Gollhofer, Daniel König
Author Information
Simon Jerger: Department of Sport and Sport Science, University of Freiburg, Schwarzwaldstraße 175, 79117, Freiburg, Germany. simon.jerger@sport.uni-freiburg.de. ORCID
Patrick Jendricke: Department of Sport and Sport Science, University of Freiburg, Schwarzwaldstraße 175, 79117, Freiburg, Germany.
Christoph Centner: Department of Sport and Sport Science, University of Freiburg, Schwarzwaldstraße 175, 79117, Freiburg, Germany.
Kevin Bischof: Department for Nutrition, Exercise and Health, Centre of Sports Science, University of Vienna, Auf Der Schmelz 6, 1150, Vienna, Austria.
Jan Kohl: Department of Sport and Sport Science, University of Freiburg, Schwarzwaldstraße 175, 79117, Freiburg, Germany.
Simon Keller: Department of Sport and Sport Science, University of Freiburg, Schwarzwaldstraße 175, 79117, Freiburg, Germany.
Albert Gollhofer: Department of Sport and Sport Science, University of Freiburg, Schwarzwaldstraße 175, 79117, Freiburg, Germany.
Daniel König: Department for Nutrition, Exercise and Health, Centre of Sports Science, University of Vienna, Auf Der Schmelz 6, 1150, Vienna, Austria.
BACKGROUND: First evidence indicates that the supplementation of specific collagen peptides (SCP) is associated with a significant improvement in running performance in physically active women; however, it is unclear if the same is true in males. The purpose of the present study was to investigate the effects of a concurrent training program including 60 min of continuous moderate intensity running training and 15 min of dynamic resistance training combined with supplementation of SCP on parameters of running performance in moderately trained males. METHODS: In a double-blind, placebo-controlled, randomized trial, participants performed a 12 weeks concurrent training and ingested 15 g of SCP [treatment group (TG)] or placebo [control group (CG)] daily. Before and after the intervention, running endurance performance was measured by a 1-h time trial on a running track. Velocity at the lactate threshold (V) and at the individual anaerobic threshold (V) were assessed on a treadmill ergometer. Body composition was evaluated by bioelectrical impedance analysis. RESULTS: Thirty-two men (28.4 ± 5.2 years) completed the study and were included in the analysis. After 12 weeks, TG had a statistically significant (p ≤ 0.05) higher increase in running distance (1727 ± 705 m) compared to the CG (1018 ± 976 m) in the time trial. V increased in the TG by 0.680 ± 1.27 km h and slightly decreased by - 0.135 ± 0.978 km h in the CG, resulting in statistically significant group differences (p ≤ 0.05). A significantly higher improvement in V (p ≤ 0.05) was shown in the TG compared with the CG only (1.660 ± 1.022 km h vs 0.606 ± 0.974 km h; p ≤ 0.01). Fat mass decreased (TG - 1.7 ± 1.6 kg; CG - 1.2 ± 2.0 kg) and fat free mass increased (TG 0.2 ± 1.2 kg; CG 0.5 ± 1.3 kg) in both groups with no significant group differences. CONCLUSION: In summary, supplementation with 15 g of SCP improved running performance in a 1-h time trial and enhanced indicators of endurance capacity at submaximal exercise intensities such as an increased velocity at the lactate as well as the anaerobic threshold more effectively than CT alone. TRIAL REGISTRATION: ETK: 123/17; DRKS-ID: DRKS00015529 (Registered 07 November 2018-Retrospectively registered); https://drks.de/search/de/trial/DRKS00015529.
